Galavit, rectal, 100 mg 10 pcs

Pharmacotherapeutic group:

An immunomodulatory and anti-inflammatory agent.

TAC code: L03, G02.

Pharmacological properties:

Pharmacodynamics

The mechanism of action of the drug is associated with its ability to regulate

the functional and metabolic activity of cells of innate and adaptive immunity (monocytes, macrophages, neutrophils, natural killers, etc.). Galavit normalizes phagocytic activity of monocytes/ macrophages, bactericidal activity of neutrophils and cytotoxic activity of NK-cells.

With this, by restoring reduced activity of cells of innate and adaptive immunity, the preparation increases resistance of the body to infectious diseases.

In addition Galavit normalizes antibody formation and increases functional activity (affinity) of antibodies.

In case of inflammatory diseases the preparation reversibly inhibits for 6-8 hours the excessive synthesis by hyperactivated macrophages of tumor necrosis factor-α, interleukin-1, interleukin-6 and other pro-inflammatory cytokines the level of which determines the degree of inflammatory reactions, their

cyclic activity as well as the severity of intoxication of the body. Galavit decreases the production of reactive oxygen species by hyperactivated macrophages, thus reducing the level of oxidative stress and protecting tissues and organs from the damaging effects of radicals.

The drug has no allergizing, mutagenic, embryotoxic, teratogenic and carcinogenic action.

Pharmacokinetics

Extracted from the body mainly through the kidneys. After rectal administration

The elimination half-life is 40-60 minutes. The main pharmacological effects are observed within 72 hours. Aminodihydrophthalazindione sodium in suppositories when administered rectally has high bioavailability, due to which both local and expressed systemic effects are achieved.

Indications

As an immunomodulatory and anti-inflammatory agent in the complex therapy of immunodeficiency conditions in adults and adolescents over 12 years of age:

– infectious and inflammatory urogenital diseases (urethritis of chlamydial and trichomonas etiology, chlamydial prostatitis, acute and chronic salpingoophoritis, endometritis);

– purulent-inflammatory diseases of the pelvic organs;

– chronic recurrent diseases caused by the herpes virus;

– diseases caused by the papilloma virus;

– postoperative rehabilitation of patients with uterine fibroids;

– complications of the postoperative period in women of reproductive age;

– postoperative purulent-septic complications and their prevention (including in cancer patients);

– chronic recurrent furunculosis, erysipelas;

– nonspecific prevention and treatment of influenza and acute respiratory infections.

– inflammatory diseases of the mucous membrane of the mouth and throat,

periodontal diseases;

– viral hepatitis;

– infectious intestinal diseases accompanied by intoxication

and/or diarrhea;

– peptic ulcer of the stomach and duodenum;

– asthenic conditions, neurotic and somatoform disorders, decreased physical performance (including among athletes); mental, behavioral and post-withdrawal disorders in alcohol and drug addiction.

Pharmacological effect

Pharmacotherapeutic group:

Immunomodulatory and anti-inflammatory agent.

ATX code: L03, G02.

Pharmacological properties:

Pharmacodynamics

The mechanism of action of the drug is associated with its ability to regulate

functional and metabolic activity of innate and adaptive immune cells (monocytes, macrophages, neutrophils, natural killer cells, etc.). Galavit normalizes the phagocytic activity of monocytes/macrophages, the bactericidal activity of neutrophils and the cytotoxic activity of NK cells.

At the same time, by restoring the reduced activity of innate and adaptive immune cells, the drug increases the body’s resistance to infectious diseases.

In addition, Galavit normalizes antibody formation and increases the functional activity (affinity) of antibodies.

In inflammatory diseases, the drug reversibly inhibits for 6-8 hours the excessive synthesis of tumor necrosis factor-α, interleukin-1, interleukin-6 and other pro-inflammatory cytokines by hyperactivated macrophages, the level of which determines the degree of inflammatory reactions, their

cyclicality, as well as the severity of intoxication of the body. Galavit reduces the production of reactive oxygen species by hyperactivated macrophages, thereby

thereby reducing the level of oxidative stress and protecting tissues and organs from the destructive effects of radicals.

Normalization of excessively increased functional activity of phagocytic cells leads to the restoration of their antigen-presenting and regulatory functions, and a decrease in the level of autoaggression.

The drug has no allergenic, mutagenic, embryotoxic, teratogenic or carcinogenic effects.

Pharmacokinetics

It is excreted from the body mainly through the kidneys. After rectal use

The half-life is 40-60 minutes. The main pharmacological effects are observed within 72 hours. Aminodihydrophthalazindione sodium in suppositories when administered rectally has high bioavailability, and therefore both local and pronounced systemic effects are achieved.

Special instructions

To prevent urogenital infection, it is recommended to consider simultaneous treatment of the sexual partner.

Effect on the ability to drive vehicles and machinery: Not studied.

Active ingredient

Sodium aminodihydrophthalazindione

Composition

Active ingredient:

sodium aminodihydrophthalazindione (Galavit®) – 100 mg;

excipients:

vitepsol W-35 (fatty acid glycerides) – 575 mg,

vitepsol H-15 (fatty acid glycerides) – 575 mg.

Pregnancy

The use of the drug is contraindicated during pregnancy and breastfeeding.

Contraindications

Hypersensitivity to Galavit and other components of the drug, pregnancy and breastfeeding, children under 12 years of age.

Side Effects

In rare cases, allergic reactions are possible. If you experience the side effects listed in the instructions or they get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

With simultaneous use, it is possible to reduce the course doses of antibiotics. There are no cases of incompatibility with other drugs.

Overdose

No cases of overdose have been reported.

Storage conditions

Store at a temperature not exceeding 25°C, protected from light.

Keep out of the reach of children.

Shelf life

3 years.

Do not use after the expiration date indicated on the carton.

Manufacturer

Selvim, Russia